Salute e Benessere

Embla Medical Expands Support for Ukrainian Amputees with New Kyiv Clinic and…

The initiative responds to an unprecedented national need. Since 2022, the Ukrainian government estimates that more than 50,000 people have suffered amputations due to war-related trauma, with numbers continuing to rise. Embla Medical has been actively supporting the development of Ukraine's prosthetic sector over the past several years, and the new clinic and initiative further strengthen that commitment. The initiative responds to an unprecedented national need. Since 2022, the Ukrainian...
PR Newswire
06/11/2025

Australian Sleep Tech Company Launches a Smart Ring to Transform Sleep & Health…

Why another Ring? While smart rings are rapidly becoming the future of health tracking, offering greater accuracy and more comfort than wrist-based devices, the company is looking far beyond just monitoring. With the retimer Ring, RTPL takes the next step by leveraging its legacy, and the progress in sensor technology and AI, to offer sleep, health and activity tracking, with more exciting features planned for circadian health, apnea and insomnia. "retimer Ring isn't just...
PR Newswire
06/11/2025

Growth in revenue and operating profit

Trading statement for Q1 2025/26 (1 July - 30 September 2025) Growth in revenue and operating profit Revenue was up by 8% in Q1 2025/26 (11% at constant exchange rates) to DKK 124.6 million from DKK 115.6 million in the year-earlier period. The Q1 performance reflected continued growth in sales of instruments, consumables and services. Moreover, ChemoMetec is experiencing growing interest in its technology, not least the XcytoMatic platform, and this trend is expected to continue,...
Nasdaq GlobeNewswire
06/11/2025

Genmab Announces Financial Results for the Nine Months of 2025

November 6, 2025 Copenhagen, Denmark;Interim Report for the Nine Months Ended September 30, 2025Highlights Announcement of Genmab’s proposed acquisition of Merus N.V. (Merus)Genmab revenue increased21% compared to the first nine months of 2024 , to $2,662 millionFDA granted BTD to Rina-S ®in advanced endometrial cancerEpcoritamab Phase 3 EPCORE ®FL-1 trial met dual primary endpoints of ORR and PFS, demonstrating statistically significant and...
Nasdaq GlobeNewswire
06/11/2025

Pharmacovigilance Market to Reach $26.2 billion, Globally, by 2034 at 12.3%…

Market Introduction Market Introduction The pharmacovigilance market encompasses a broad range of systems, services, and technologies dedicated to monitoring, detecting, assessing, and preventing adverse effects or any other drug-related problems throughout a pharmaceutical product's lifecycle. It plays a pivotal role in ensuring drug safety, regulatory compliance, and public health, and is integral to both clinical development and post-marketing surveillance. Pharmacovigilance activities...
PR Newswire
06/11/2025

Neurovascular Devices Market worth $7.22 billion in 2030 with 9.3% CAGR |…

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=847 Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=847 Browse in-depth TOC on "Neurovascular Devices Market" 150 - Tables 70 - Figures 300 - Pages By disease pathology,the global neurovascular devices market is divided into five main segments: cerebral aneurysms, ischemic strokes, carotid artery stenosis, arteriovenous malformations and fistulas, and other...
PR Newswire
06/11/2025

Global Telehealth Market Size to Exceed USD 156.3 Billion by 2035, Rising at…

Market Highlights Market Highlights Key Regional Markets Leading the Way The Complete Study is Now Available for Immediate Access | Download the Sample Pages of this Report @ https://www.vantagemarketresearch.com/telehealth-market-1246/request-sample Free Sample Includes: Technological & Industry Momentum Why This Matters for Executives & Investors? The Telehealth market is emerging as one of the fastest-growing frontiers in healthcare digitization,...
PR Newswire
06/11/2025

Nitinotes Receives CE Mark Approval of EndoZip™, the First Fully Automated…

Obesity is one of the most urgent global health challenges, affecting more than 650 million adults worldwide. Current treatment pathways leave a significant gap between medical management such as GLP-1 therapy and invasive bariatric surgery. ESG is emerging as a minimally invasive alternative, addressing patients with obesity (BMI 30–40 kg/m²) who have not achieved success with conservative measures such as diet, exercise, or medication. Obesity is one of the most urgent global health...
PR Newswire
06/11/2025

Consortium consisting of Nordic Capital and Permira announces preliminary result…

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTIONCOPENHAGEN, Denmark, 6 November, 2025– With reference to company announcements dated 26 August 2025 (no. 24/2025), 29 September 2025 (no. 27/2025), 15 October 2025 (no. 31/2025), and 21 October 2025 (no. 33/2025) regarding the all-cash voluntary board-recommended public takeover offer to...
Nasdaq GlobeNewswire
06/11/2025

Alvotech and Advanz Pharma Receive Marketing Authorisations for Gobivaz®, a…

REYKJAVIK, ICELAND and LONDON, UK (November 06, 2025)— Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma Holdco Limited (“Advanz Pharma”), a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe, today announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted...
Nasdaq GlobeNewswire
06/11/2025

Secondary Immunodeficiencies in the spotlight at IPIC 2025: Kedrion champions…

Secondary Immunodeficiencies, particularly in patients with B-cell hematological malignancies, represent a significant clinical challenge due to their complex pathogenesis and the increased risk of life-threatening infections. Advances in cancer therapies have improved survival, but complications, in particular Hypogammaglobulinemia and infections, can compromise treatment outcomes and patient quality of life. Early diagnosis and appropriate management, including Immunoglobulin replacement…
PR Newswire
06/11/2025

Sironax Announces Three Abstracts Selected for Presentation at Neuroscience…

Society for Neuroscience Annual Meeting, November 15-19, San Diego, CA Neuroscience 2025, the Society for Neuroscience annual meeting in San Diego from November 15 to 19.Presentation details are below: Title : Development of a Highly Potent, Brain Penetrant and Allosteric RIPK1 Inhibitor for the Treatment of Neurodegenerative Diseases Session Name : Alzheimer's Disease Therapeutic Strategies: Pharmaceutical Approaches Session Number : PSTR157 Date/Time : November 17, 8 a.m. -12 p...
Nasdaq GlobeNewswire
06/11/2025

Urteste S.A. launches European multicenter clinical study of the Panuri test

Urteste S.A. launches European multicenter clinical study of the Panuri test Gdańsk, Poland – 6 November 2025 – Urteste S.A. (Warsaw Stock Exchange: URT), a company specializing in the development of innovative technology for the early detection of cancer from urine samples, has entered into a tripartite agreement with Aurevia Poland and Aurevia Oy, based in Finland, for CRO services, including the organization and management of a European clinical study of the Panuri test — an IVD...
Nasdaq GlobeNewswire
06/11/2025

Evaxion announces business update and third quarter 2025 financial results

/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, provides business update and announces third quarter 2025 financial results. Business highlights (since last quarterly update)Evaxion has seen tremendous progress in recent months with several massive achievements. We maintain a high activity level and continue to execute our plans. Highlights include: Evaxion’s Board of Directors has appointed Dr Helen...
Nasdaq GlobeNewswire
06/11/2025

Designing for Tomorrow: The 138th Canton Fair Showcases Innovations Rooted in…

Technology, meanwhile, is redefining what safety can mean in daily family life. One of the innovations at this session came from an Anhui-based company introducing an intelligent baby crib equipped with an automated rocking system that responds to a child's cry. The design not only provides hands-free comfort for parents but also extends usability from infancy up to three years of age, showcasing a thoughtful balance between convenience, safety, and functionality. Technology, meanwhile, is...
PR Newswire
06/11/2025

uniQure to Announce Third Quarter 2025 Financial Results

~ uniQure to host earnings call on Monday, November 10, 2025 at 8:30 a.m. ET ~ uniQureN.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs will report third quarter 2025 financial results before market open on Monday, November 10, 2025. Management will then host a conference call at 8:30 a.m. ET.The event will be webcast under the Events & Presentations section of uniQure’s website athttps://www.uniqure...
Nasdaq GlobeNewswire
06/11/2025

TREOS Bio Announces Publication of Phase 1b Clinical Trial Results of…

First study to report promising activity for an active immunotherapy combined with TAS-102 (LONSURF®) in late-stage MSS mCRC; TREOS advances Phase II programme with Charité – Universitätsmedizin Berlin and Junshi Biosciences Journal of Clinical Oncology - Oncology Advances of results from OBERTO-201 (NCT05130060), a Phase 1b study evaluating PolyPEPI1018, an off-the-shelf multi-peptide immunotherapy, in combination with oral chemotherapy TAS-102 (LONSURF®) for patients with refractory...
Nasdaq GlobeNewswire
06/11/2025

SkylineDx Wins 2025 BioTech Breakthrough Award for "Diagnostics Company of the…

The Merlin CP-GEP Test is a genomic assay that guides disease management decisions across all stages of melanoma and is available commercially in the U.S. and Europe. The Merlin GP-GEP Test combines clinicopathologic factors with gene expression analysis to assess a patient's risk of melanoma metastases. SkylineDx recently published a landmark study in JAMA Surgery validating Merlin CP-GEP Test's ability to accurately stratify melanoma patients by sentinel node metastasis risk, making it a…
PR Newswire
06/11/2025

The 138th Canton Fair Concludes Successfully

Exhibiting enterprises pursued innovation, intelligence and environment protection in materials, craftsmanship and supply chains. New and green products and products with independent intellectual property rights accounted for 23.3%, 23.5% and 23.9% of the total 4.6 million products respectively. AI empowerment, innovative and intelligent manufacturing, low-carbon and high-end customization were the key words throughout three phases. Humanoid robots, brain-computer interface devices, plastic-free…
PR Newswire
06/11/2025

Health and Fitness Club Market to Reach $102.3 Billion by 2024 in the short term…

Download Sample Pages of Research Overview:https://www.alliedmarketresearch.com/request-sample/A11813 Download Sample Pages of Research Overview:https://www.alliedmarketresearch.com/request-sample/A11813 Market Introduction: The health and fitness club market includes a broad range of services meant to enhance general well-being, physical health, and quality of life. These clubs include wellness centers, boutique fitness studios, conventional gyms, and specialty training facilities...
PR Newswire
06/11/2025

Tigermed Selected as "2025 Forbes China Go-International Flagship Brands" Top 30

Tigermed's selection demonstrates the growing global impact of China's biopharmaceutical innovation. As a global clinical development services provider, Tigermed operates more than 180 offices and networks worldwide with over 10,000 across North America, Europe, China, Asia-Pacific, Africa and Latin-America. We are devoted to building an integrated end-to-end platform that enables the boundless possibilities for the healthcare industry, and becoming a bridge for China biotech…
PR Newswire
06/11/2025

Novonesis delivered 8% organic sales growth in the first nine months of 2025

Novonesis delivered 8% organic sales growth in the first nine months of 2025 and narrowed full-year outlook upwards. COPENHAGEN, Denmark – November 6, 2025. Novonesis delivered 8% organic sales growth in the first nine months of 2025. Full-year outlook is narrowed upwards to 7-8%, previously 6-8%.Ester Baiget, President & CEO: "I am pleased with our performance in the first nine months, where we delivered 8% organic sales growth with solid profitability. Our performance was strong...
Nasdaq GlobeNewswire
06/11/2025

arcoris bio raises CHF 6.3 million seed round to advance next-generation…

Round co-led by Ventura Ace and ZEISS Ventures, with participation from Zürcher Kantonalbank (ZKB) and new as well as existing private investors.MUSE ®, arcoris bio’s nanotechnology platform for biomarker detection and signal amplification, enables simultaneous detection of multiple biomarkers with unprecedented ease and sensitivity.The funding will accelerate industrialization of the MUSE ®platform, expansion of strategic partnerships, and launch of new products.Schlieren,...
Nasdaq GlobeNewswire
06/11/2025

Nucleome Therapeutics founder Professor James Davies and Oxford University…

Dr. Mark Bodmer, CEO of Nucleome, commented: "Congratulations to James and his team at Oxford on this groundbreaking work. Using MCC technology, for the first time it has been possible to see 3D interactions in the nucleus inside the cell at base pair resolution. This gives us a new way of looking at how genetic variation in the human genome causes disease. At Nucleome, we are applying this transformative technology to solve the molecular basis of inflammatory diseases. This has enabled us…
PR Newswire
06/11/2025
Altri  Comunicati